 WATERTOWN, Mass., Sept. 20, 2021 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. 